CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Compass Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.83−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $155.98M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.4250 (−80.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Compass Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$56.38M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$81.09M
TTM Q2 2026
Free cash flow
-$56.38M
TTM Q2 2026
EPS, diluted
-$0.39
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $155.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.94
- Dividend yield
- –
- Free cash flow yield
- -36.14%
Fundamentals
- Revenue
- $0
- Net income
- -$73.45M
- EPS, diluted
- -$0.39
- Free cash flow
- -$56.38M
- Book value per share
- $0.89
- Diluted shares
- 187M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$81.09M
Net income
-$73.45M
EPS, diluted
-$0.39
Free cash flow
-$56.38M
Reported periodTrailing twelve months